Federal Circuit Affirms Invalidation of Purdue Pharma’s OxyContin Patents

May 20, 2016

Reading Time : 1 min

Beginning in 2011, Purdue Pharma and Grunenthal GmbH filed Hatch-Waxman lawsuits against Teva Pharmaceuticals, Amneal Pharmaceuticals, Epic Pharma and Mylan Pharmaceuticals in response to their Abbreviated New Drug Applications seeking Food and Drug Administration approval to market generic versions of OxyContin. 

After a three-week bench trial in the Teva case, the district court ruled that all of the asserted patent claims are invalid. The district court then entered orders of dismissal in the cases against Amneal, Epic and Mylan based on collateral estoppel. Purdue and Grunenthal appealed the final judgment in the Teva case and the dismissal orders in the Amneal, Epic and Mylan cases.

On appeal, the Federal Circuit affirmed the district court’s invalidity determinations. The Court of Appeals rejected Purdue’s argument that its discovery of the source of the toxic impurity minimized in its claimed drug product supported patentability because the solution did not depend on the source of the impurity. The Federal Circuit also affirmed the district court’s dismissal of the actions against Amneal, Epic and Mylan for collateral estoppel because Purdue did not present any persuasive reasons why the Teva invalidity ruling should not apply to the other cases.

The Federal Circuit denied Purdue’s petition for panel rehearing and rehearing en banc.

Purdue Pharma L.P. v. Epic Pharma, LLC, No. 14-1294 (Fed. Cir.).

Share This Insight

Previous Entries

IP Newsflash

February 24, 2026

The Southern District of Florida recently dismissed a complaint without prejudice because the allegations used a form of “shotgun pleading.” The court explained that a shotgun pleading includes those where every count incorporates every preceding paragraph into each cause of action, and that dismissal of such pleadings was required under Eleventh Circuit precedent.

...

Read More

IP Newsflash

February 20, 2026

The Federal Circuit recently addressed whether the PTO must conduct notice‑and‑comment rulemaking before issuing instructions that guide how the Board should exercise discretion at the institution stage of IPRs. The court held that no such rulemaking is required. Instructions to the Board regarding its use of the Director’s delegated discretionary authority not to institute review are merely general statements of policy exempt from notice-and-comment rulemaking.  

...

Read More

IP Newsflash

February 18, 2026

The District Court for the District of Delaware recently invalidated claims directed to a panoramic objective lens for lack of enablement, holding the claims impermissibly recited a single element in means‑plus‑function form. Under § 112, ¶ 6, “[a]n element in a claim for a combination may be expressed as a means or step for performing a specified function….” By its plain terms, the statute permits means‑plus‑function claiming only in the context of a “combination.” In other words, a claim may not consist solely of a single means‑plus‑function element. Claims drafted as a single means are invalid for lack of enablement as a matter of law.

...

Read More

IP Newsflash

February 13, 2026

In an ANDA litigation, the District of Delaware recently denied the defendants’ motion to compel the production of correspondence between the plaintiffs’ testifying expert and a third-party analyst who had performed experiments and provided data used by the testifying expert. The court found that the scope of material sought by the motion was overbroad and disproportionate to the needs of the case.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.